secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-109119
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor reports Q3 net loss $24.6M; HOPE-3 topline DMD data expected in Q4 2025
--------------------------------------------------------------------------------

- Net loss of $24.6M ($0.54/share) vs $12.6M ($0.38) in Q3 2024; operating expenses $26.3M, up 72%.
- Revenue $0 vs $2.3M in prior year; prior revenue from Nippon Shinyaku milestones now fully recognized.
- Cash $98.6M as of Sept 30, down from $151.5M at Dec 31, 2024; runway into Q4 2026.
- Topline results from HOPE-3 Phase 3 trial of Deramiocel for Duchenne cardiomyopathy expected in Q4 2025.
- FDA supported submitting HOPE-3 results for BLA resubmission (Type A meeting); PLI completed with all 483 observations addressed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/0001104659-25-109119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer